UPA系统在肿瘤患者中的检测意义及研究进展  

Urokinase system of plasminogen activation and its measurement in cancer

作　　者：沈倩雯[1] 金冶宁[1] 

机构地区：[1]上海交通大学医学院瑞金医院肿瘤放化疗科,上海200025

出　　处：《现代肿瘤医学》2008年第12期2207-2209,共3页Journal of Modern Oncology

摘　　要：肿瘤发生侵袭并最终转移,肿瘤细胞必须通过对基底膜及细胞外基质成分的附着、黏附和侵袭来穿透细胞和基质屏障。这个过程由细胞因子及生长因子严格调节,并需要肿瘤相关蛋白水解酶的表达。其中,一个重要的蛋白水解酶就是尿激酶系统。本文对该系统的成分,功能以及其在肿瘤中,尤其在乳腺癌,前列腺癌,胃肠道肿瘤中的作用及最新研究进展进行综述。For a tumor to become invasive and ultimately metastasize, tumor cells must cross cellular and matrix boundaries by attaching to,interacting with, and invading components of the basement membrane and extracellular ma- trix. This multistep process is tightly regulated by cytokines and gTowth factors and requires the expression of tumor - associated proteases. One of the main protease systems involved in tumor cell invasion and metastasis is the Urokinase system. The components of the system include the urokinase plasminogen activator （ UPA）, its cell surface receptor uro- kinase plasminogen activator receptor （UPAR） ,and its naturally occurring inhibitors plasminogen activator inhibitors 1 and 2 （ PAI - 1 and PAl - 2 ）. This paper reviews the role of the Urokinase system in cancer, especially in breast cancer,prostate cancer,gastrointestinal cancer and its advances in research.

关 键 词：尿激酶系统 UPA 肿瘤 

分 类 号：R730.23[医药卫生—肿瘤]